DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Elafibranor
Elafibranor
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
Disease Progression and Pharmacological Intervention in a Nutrient‑Defcient Rat Model of Nonalcoholic Steatohepatitis
A61p1/16 (2006.01) A61p3/00 (2006.01) Km, Ml, Mr, Ne, Sn, Td, Tg)
The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development
Lessons from Liver-Specific PPAR-Null Mice
Pemafibrate (K-877), a Novel Selective Peroxisome Proliferator-Activated
Peroxisome Proliferator-Activated Receptors and Their Novel Ligands As Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease
Exploration and Development of PPAR Modulators in Health and Disease: an Update of Clinical Evidence
Peroxisome Proliferator-Activated Receptors
Metabolic Disease
Combination for Therapy Non-Alcoholic Steatohepatitis: Rationale, Opportunities and Challenges
Targeting Ppars
FDA-Approved Drug Library Mini (96-Well)
Saroglitazar in Patients with Non-Alcoholic Fatty Liver Disease And
Product List
The Effect of Antidiabetic Medications on Non-Alcoholic Fatty Liver Disease
The Role of Lipid Sensing Nuclear Receptors (Ppars and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD
WO 2018/193007 Al 2018/193007
Top View
PPAR Agonists and Metabolic Syndrome: an Established Role?
Synthetic and Natural Peroxisome Proliferator‑Activated Receptor (PPAR) Agonists As Candidates for the Therapy of the Metabolic Syndrome
Potential Treatment for Duchenne Muscular Dystrophy (DMD) † † † † † Bharat Lagu,*, Arthur F
Exploration and Development of PPAR Modulators in Health and Disease : an Update of Clinical Evidence
C07D 491/107 (2006.01) — with International Search Report (Art
Diabetes and Obesity Research Tools
Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors
Elafibranor for the Treatment of NAFLD: One Pill, Two Molecular Targets and Multiple Effects in a Complex Phenotype
Drug Repurposing Compound Library Plus (96-Well)
Book of Abstracts
Lanifibranor KOL Breakfast
Cymabay Is Out, but for Genfit the Band Plays On
Statins, Fibrates, and Other Peroxisome Proliferator-Activated Receptor Agonists for the Treatment of Cholestatic Liver Diseases
Download the Programme Book ILC 2019
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
Drug Repurposing Compound Library (96-Well)
Fatty Liver Disease (Nafld/Nash)
Current and Upcoming Pharmacotherapy for Non-Alcoholic Fatty Liver Disease Yaron Rotman,1 Arun J Sanyal2